Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 9Other hematologic neoplasm 5Tumor-Agnostic 1Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Melanoma 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Renal Cell 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mycosis Fungoides 1Mesothelioma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Hodgkin Disease 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 40Nivolumab 18trametinib 13Cyclophosphamide 13dabrafenib 11Vemurafenib 10Interleukin-2 10Ipilimumab 9fludarabine 7Docetaxel 7fludarabine phosphate 6cemiplimab 6Paclitaxel 6Cisplatin 6Carboplatin 6atezolizumab 5Radiotherapy 5Drug Therapy 5Dacarbazine 5Blood Specimen Collection 5Biopsy 5poly ICLC 4binimetinib 4Therapeutics 4Psychiatric Rehabilitation 4sotigalimab 3montanide ISA 51 3encorafenib 3cobimetinib 3budigalimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × obinutuzumab × Dermatologic × Clear all
NCT04787042 2024-11-15

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Simcha IL-18, Inc.

Phase 1/2 Recruiting
316 enrolled
BreastDermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡